Abstract
Long-acting muscarinic receptor antagonists (LAMAs) are the cornerstone for the treatment of chronic obstructive pulmonary disease (COPD); furthermore, tiotropium is approved as add-on therapy in severe asthmatic patients. Accumulating evidence suggests that LAMAs may modulate airway contractility and airway hyperresponsiveness not only by blocking muscarinic acetylcholine receptors (mAchRs) expressed on airway smooth muscle but also via anti-inflammatory mechanisms by blocking mAchRs expressed on inflammatory cells, submucosal glands, and epithelial cells. The aim of this systematic review, performed according to the PRISMA-P guidelines, was to provide a synthesis of the literature on the anti-inflammatory impact of muscarinic receptor antagonists in the airways. Most of the current evidence originates from studies on tiotropium, that demonstrated a reduction in synthesis and release of cytokines and chemokines, as well as the number of total and differential inflammatory cells, induced by different pro-inflammatory stimuli. Conversely, few data are currently available for aclidinium and glycopyrronium, whereas no studies on the potential anti-inflammatory effect of umeclidinium have been reported. Overall, a large body of evidence supports the beneficial impact of tiotropium against airway inflammation. Further well-designed randomized controlled trials are needed to better elucidate the anti-inflammatory mechanisms leading to the protective effect of LAMAs against exacerbations via identifying suitable biomarkers.
Keywords: muscarinic receptor antagonist, LAMA, tiotropium, inflammation, systematic review
Introduction
Long-acting muscarinic receptor antagonists (LAMAs) are central to the maintenance treatment of stable chronic obstructive pulmonary disease (COPD).1 Furthermore, tiotropium bromide (TIO) is approved as add-on therapy in severe asthmatic patients with a history of exacerbations at Steps 4 and 5.2,3
Airflow restriction, along with small airway involvement, and pathological structural changes in the airways are hallmark features of chronic obstructive respiratory disorders. COPD and asthma may share some symptoms and clinical characteristics; however, these disorders are characterized by specific pathophysiological patterns, and the mechanism of bronchospasm is generally different: mainly hyperinflation in COPD and airway hyperresponsiveness (AHR) in asthma. Moreover, symptoms and clinical presentation in COPD may be caused by a dysfunction of the autonomic nerve control of the airway smooth muscle (ASM) tone.4 Vagal innervation is the main cause of the bronchoconstrictive airway responses and represents the reversible component of airflow obstruction, thus making muscarinic receptor antagonists effective in the management of chronic obstructive airway disorders.5,6 Up-regulation of acetylcholine (Ach) release is associated with increased ASM contractility, mucus hypersecretion, and enhanced parasympathetic tone in airway inflammation of both COPD and asthma.6 Muscarinic Ach receptor (mAchR) subtypes (M1, M2 and M3), widely expressed in the airways, are involved in airway remodelling and inflammation.6
Accumulating evidence has indicated that LAMAs may modulate airway contractility and AHR not only by blocking mAchRs expressed on the ASM but also via anti-inflammatory mechanisms by blocking mAchRs expressed on inflammatory cells, submucosal glands, and epithelial cells.7,8 Moreover, non-neuronal Ach released from airway epithelium modulates ASM contractility in small airways and potentially also inflammation, with LAMAs preventing these detrimental effects.9
To date, no systematic reviews on the anti-inflammatory effect of muscarinic receptor antagonists have been performed in respiratory medicine. Therefore, the aim of this systematic review was to provide a synthesis of the literature on the anti-inflammatory impact of muscarinic receptor antagonists in the airways.
Materials and Methods
Detailed methods are reported in the Supplementary Appendix.
Review Question
To assess the impact of muscarinic receptor antagonists on airway inflammation.
Search Strategy and Study Eligibility
This qualitative synthesis of the current literature was performed in agreement with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P, submission ID: 170285).10 The flow diagram is reported in Supplementary Figure 1 and the PRISMA-P checklist in Supplementary Table 1.
A comprehensive literature search was performed for in vitro, in vivo, and clinical studies, written in English and evaluating the impact of muscarinic receptor antagonists on airway inflammation. The search was performed in MEDLINE in order to provide reports available from the last decade up to 5th June, 2020 for in vitro and in vivo studies; clinical studies were searched with no time limitation. The research string was as follows: (((muscarinic antagonists) OR antimuscarinic OR tiotropium OR glycopyrronium OR umeclidinium OR aclidinium OR ipratropium OR oxitropium) AND inflammation) NOT review.
Study Selection
In vitro, in vivo, and clinical studies reporting the impact of muscarinic receptor antagonists on airway inflammation were included in this systematic review. Research papers evaluating the anti-inflammatory activity of muscarinic receptor antagonists in combination with other therapeutic agents were excluded.
Data Extraction
Data from included studies were extracted and checked for study and year of publication, type of study, type of cells, animals, and donors, pro-inflammatory stimuli, number of patients or donors or animals, gender, treatments, route of administration, type of biological samples, and investigated outcomes.
Endpoints
The endpoint of this systematic review was the impact of muscarinic receptor antagonists on airway inflammation.
Strategy for Data Analysis
Data from original papers were extracted and reported via qualitative synthesis.
Quality of Studies and Risk of Bias
The summary of the risk of bias for each included clinical study was analyzed via the Jadad score and the Cochrane Risk of Bias 2 (RoB 2).11,12
Results
Of the 268 potentially relevant records identified in the initial search, 49 studies were deemed eligible for a qualitative analysis (Supplementary Table 2). Detailed information concerning the study characteristics and the pro-inflammatory stimuli used in the included studies are described in the Supplementary Appendix.
Anti-Inflammatory Effect of Muscarinic Receptor Antagonists in vitro
An overview concerning the anti-inflammatory effect of muscarinic receptor antagonists in vitro is reported in Table 1.
Table 1.
Impact of Muscarinic Receptor Antagonists on Humoral and Cellular Responses Upon Induction of a Pro-Inflammatory Stimulus in vitro. Statistically Significant Results with a P<0.05 are Reported in the Table
| Investigated Treatment | Pro-Inflammatory Stimulus | Outcomes Investigated in the in vitro Studies | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IL-1β | IL-4 | IL-5 | IL-6 | IL-8 | IL-13 | IFN-γ | TNF-α | HDAC Activity | SIRT1 | NF-κB Activity | CCL5 | GM-CSF | Proteolytic Caspase Activity | Total Inflammatory Cells | Neutrophils | Apoptotic CD+T Cells | LTB4 | MIP α/β | MMP-1 | MMP-2 | MMP-9 | TIMP-1 | TIMP-2 | ||
| ACL | CSE | / | / | / | / | ≈23,↓24 | / | / | / | ≈23 | ≈23 | / | / | / | / | / | / | / | / | / | / | / | / | / | / |
| LPS | ↓24 | / | / | / | ↓24 | / | / | / | ≈24 | / | / | ↓24 | ↓24 | / | / | / | / | / | / | / | / | ↓24 | / | / | |
| Cch | / | / | / | / | ↓24 | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | |
| GLY | CSE | / | / | / | / | ↓25 | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / |
| Ach | / | / | / | / | ↓25 | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | |
| TIO | CSE | / | / | / | / | ↓13 | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / |
| Supernatant of the sputum of COPD patients | / | / | / | / | ↓14 | / | / | / | ↑14 | / | ↓14 | / | / | / | / | ↓ percentage of adhering neutrophils, MAC-1 expression on neutrophils15 | / | / | / | / | / | / | / | / | |
| rhIL-17A | / | / | / | / | ↓14 | / | / | / | ↑14 | / | ↓14 | / | / | / | / | / | / | / | / | / | / | / | / | / | |
| IL-1β | / | / | / | ≈18 | ↓18 | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | |
| IL-1β and Cch | / | / | / | ↓18 | ↓18 | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | |
| Ach | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | ↓ percentage of adhering neutrophils, MAC-1 expression on neutrophils15 | / | / | / | / | / | / | / | / | |
| Ach and TGF-β1 | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | ↓ percentage of adhering neutrophils, MAC-1 expression on neutrophils15 | / | / | / | / | / | / | / | / | |
| TGF-β | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | ↓19 | ↓19 | / | ≈19 | ≈19 | |
| LPS | / | / | / | ≈20 | ↓17,≈20 | / | / | ↓20 | / | / | ↓17 | / | ≈20 | / | / | ↓20 | / | ≈20 | ≈20 | / | / | / | / | / | |
| PHA | / | ≈22 | ↓22 | / | / | ↓22 | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | |
| OVA | / | / | ↓22 | / | / | ↓22 | ↓22 | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | |
| Rhinovirus type-14 | ↓16 | / | / | ↓16 | ↓16 | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | |
| NA | / | / | / | / | / | / | / | / | / | / | ↓21 | / | / | ↑ caspase 3 and 821 | / | / | ↑ CD3+ and CD8+21 ↓ CD4+21 |
/ | / | / | / | / | / | / | |
| 4-DAMP | OVA | / | ≈22 | ↓22 | / | / | ↓22 | ↓22 | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / |
| LPS | / | / | / | / | / | / | / | ↓26 | / | / | ↓26 | / | / | / | / | ↓20 | / | / | / | / | / | / | / | / | |
| IB | LPS | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | ≈20 | / | / | / | / | / | / | / | / |
Abbreviations: Ach, acetylcholine; ACL, aclidinium; Cch, carbachol; COPD, chronic obstructive pulmonary disease; CSE, cigarette smoke extract; GLY, glycopyrronium; HDAC, histone deacetylase; IB, ipratropium bromide; IFN, interferon; IL, interleukin; LPS, lipopolysaccharide; MAC-1, macrophage-1 antigen; MIP, macrophage inflammatory protein; MMP, matrix metalloproteinase; NA, not available; NF-kB, nuclear factor kappa-light-chain-enhancer of activated B cells; NLF, nasal lavage fluid; OVA, ovalbumin; PHA, phytohemagglutinin; rhIL-17A, recombinant human IL-17A; SIRT1, sirtuin 1; TGF- β1, tumor growth factor-beta 1; TIMP, tissue inhibitor of metalloproteinase; TIO, tiotropium bromide or tiotropium bromide hydrate; TNF-α, tumor necrosis factor-alpha; 4-DAMP, 1,1-dimethyl-4-diphenylacetoxypiperidinium iodide.
Tiotropium Bromide
In immortalized 16HBE human bronchial epithelial cells stimulated by cigarette smoke (CS) extract (CSE), TIO 100 nM reduced the over-expression of interleukin (IL)-8.13 TIO also inhibited the gene and protein over-expression of IL-8, reduced the translocation of nuclear inhibitor kappa kinase alpha (Iκκα), and improved the expression and activity of histone deacetylase 2 (HDAC2) following simulation with the supernatant of sputum collected from COPD patients or recombinant human IL-17A.14 TIO suppressed the neutrophil adhesion to epithelial cells after stimulation with supernatant of the sputum collected from COPD patients, tumor growth factor-beta 1 (TGF-β1), and/or Ach, by inhibiting the over-expression of macrophage-1 antigen (MAC-1).15
TIO 33 pM, corresponding to the plasma concentration after inhalation of TIO 18 μg, reduced the infection-induced release of IL-1β, IL-6, and IL-8 in human tracheal surface epithelial cells derived from either healthy or COPD patients stimulated with rhinovirus type-14 infection.16
In immortalized BEAS-2B human bronchial epithelial cells stimulated with lipopolysaccharide (LPS), TIO inhibited the gene and protein over-expression of IL-8, and suppressed the increased activity of nuclear factor-κB (NF-κB) via inactivating p50 and p65 subunits.17
TIO 10 nM–1 μM reduced the release of IL-8 but not of IL-6 from lung fibroblasts stimulated by IL-1β. After stimulation with both IL-1β and carbachol (Cch), TIO counteracted the over-expression of both IL-6 and IL-8.18 TIO reduced the increased release and activity of matrix metalloproteinase (MMP)-1 and MMP-2 induced by TGF-β, but did not modulate the gene over-expression of tissue inhibitor of metalloproteinases (TIMP)-1 and TIMP-2.19 TIO also reduced the gene over-expression of IL-8 and suppressed the increased activity of NF-κB induced by LPS stimulation.17
TIO 30 nM inhibited the neutrophil migration rate and tumor necrosis factor-alpha (TNF-α) release following a challenge with the supernatant from alveolar macrophages derived from COPD patients and stimulated by LPS. Conversely, TIO showed no modulatory effect on IL-6, IL-8, leukotriene B4 (LTB4), granulocyte-macrophage colony-stimulating factor (GM-CSF), and macrophage inflammatory protein (MIP)-α/-β.20 In neutrophils stimulated with the supernatant of the sputum collected from COPD patients TIO 100 nM reduced the over-expression of MAC-1.15 TIO 20 nM increased the percentage of apoptotic CD3+ and CD8+ peripheral blood T (PBT)-cells isolated from COPD patients and improved the proteolytic activity of caspases 3 and 8. TIO also reduced the number of apoptotic CD4+ cells, and blocked the phosphorylation of the inhibitor of NF-κB (IκB)-α, leading to an increase in IκB-α concentration.21 In human peripheral blood mononuclear cells isolated from asthmatic patients stimulated with phytohemagglutinin (PHA), the over-release of IL-5 and IL-13 was suppressed by TIO 1–100 μg/mL, without affecting the level of IL-4.22 In spleen cells derived from mice and stimulated with ovalbumin (OVA), TIO 50 μg/mL inhibited the over-expression of IL-5, IL-13, and interferon-gamma (IFN-γ).22
Aclidinium
In human 16HBE immortalized bronchial epithelial cells, aclidinium (ACL) 10 nM did not counteract the CSE-mediated protein and gene over-expression of IL-8, and the reduced nuclear expression of sirtuin 1, HDAC2, and HDAC3.23
ACL 0.1 nM–1 μM decreased the release of IL-1β, IL-8, MMP-9, C-C motif chemokine ligand 5, and GM-CSF, but did not modulate the expression of HDAC2 in neutrophils from stable COPD patients exposed to CSE or challenged with LPS.24
Glycopyrronium Bromide
In human primary bronchial epithelial cells, glycopyrronium (GLY) 100 nM suppressed the gene and protein over-expression of IL-8 induced by CSE and Ach.25
Ipratropium Bromide
Ipratropium bromide (IB) 30 nM did not modify the migration rate of neutrophils following a challenge with the supernatant from alveolar macrophages derived from COPD patients and stimulated by LPS.20
1,1-Dimethyl-4-Diphenylacetoxypiperidinium Iodide
1,1-dimethyl-4-diphenylacetoxypiperidinium iodide (4-DAMP) 10–100 μM inhibited the release of TNF-α and the degradation of IκB-α in alveolar macrophages challenged with LPS.26 4-DAMP also reduced the migration rate of neutrophils following a challenge with the supernatant from alveolar macrophages derived from COPD patients and stimulated by LPS.20 In spleen cells derived from mice and stimulated with OVA, 4-DAMP 5–100 μg/mL reduced the over-release of IL-5, IL-13, and IFN-γ, with no modulatory effect on IL-4.22
Anti-Inflammatory Effect of Muscarinic Receptor Antagonists in Laboratory Animals
An overview concerning the anti-inflammatory effect of muscarinic receptor antagonists in laboratory animals is reported in Tables 2 and 3.
Table 2.
Impact of Muscarinic Receptor Antagonists on Humoral Response Upon Induction of a Pro-Inflammatory Stimulus in Laboratory Animals. Statistically Significant Results with a P<0.05 are Reported in the Table
| Investigated Treatment and ROA | Pro-Inflammatory Stimulus | Outcomes Investigated in the in vivo studies Carried Out on Laboratory Animals | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IL-1β | IL-4 | IL-5 | IL-6 | IL-8 | IL-13 | IL-17A | IFN-γ | NF-κB Activity | MCP-1 | MIP-1 | MIP-2 | KC | PDCD5 | TNF-α | MMP-2 | MMP-9 | TGF-β1 | TIMP-1 | ||
| TIO inh. | OVA | / | BALf:↓36,39 acute and chronic challenge;22 ↑ acute challenge;40 ≈ chronic challenge.40 Lung:↓36 |
BALf:↓39 acute and chronic challenge;22 ↑ acute challenge;40 ≈ chronic challenge.40 Lung:↓36 | / | / | BALf:↓39 acute and chronic challenge;22 ↑ acute challenge;40 ≈ chronic challenge40 | / | BALf:↑36 Lung:↑36 |
/ | / | / | / | / | BALf:↓35 Lung:↓35 |
/ | / | Lung:↓36 | BALf: ↓ chronic challenge22 | Lung:≈36 |
| OVA + exposure to PM | / | / | BALf:↓37 | BALf:↓37 | / | BALf:↓37 | / | BALf:≈37 | / | / | / | / | BALf:↓37 | / | / | / | / | / | / | |
| CS | BALf:↓28,29 Lung:↓28,29 | / | / | BALf:↓30,31 | BALf:↓31 | / | / | / | / | BALf:↓28–31 Lung:↓28,29 |
BALf:↓30 | BALf:↓30 | BALf:↓28,30 Lung:↓28 |
/ | BALf:↓28–31 Lung:↓28,29 | / | Lung:↓29 | BALf:↓29 Lung:↓29 | Lung:↑29 | |
| CS + H1N1 infection | Lung:≈27 | / | / | Lung:↓27 | / | / | / | Lung:↓27 | / | / | / | / | Lung:≈27 | / | Lung:≈27 | / | / | / | / | |
| CS + RSV infection | Lung:≈27 | / | / | Lung:↓27 | / | / | / | Lung:↓27 | / | / | / | / | Lung:≈27 | / | Lung:↓27 | / | / | / | / | |
| OD | / | BALf:↓34*. Lung:≈34* |
/ | BALf:↓34*. Lung:≈34* | / | BALf:≈34*. Lung:≈34* |
Lung:≈34* | / | / | BALf:≈34* | BALf:≈34*. Lung:≈34* |
/ | Lung:≈34* | / | BALf:≈34*. Lung:≈34* | / | / | / | / | |
| RB | Lung: ↓ 40%IRB, 50%IRB, 60%ERB, and 40%/60%CRB45 | / | / | Lung: ↓ 40%IRB, 50%IRB, 60%ERB, and 40%/60%CRB45 | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | |
| CdCl2 | BALf:≈47 | / | / | / | / | / | / | / | / | / | / | / | / | / | BALf:≈47 | BALf:↓47 | BALf:≈47 | / | / | |
| LPS | / | / | / | BALf:↓30 | / | / | / | / | / | BALf:≈30 | BALf:≈30 | BALf:≈30 | / | / | BALf:≈30 | / | / | / | / | |
| Acidic solution (with HCl) | / | / | / | / | BALf:↓46 | / | / | / | / | / | / | / | / | / | / | / | / | / | / | |
| BCQB inh. | CS | BALf:↓28 Lung:↓28 | / | / | / | / | / | / | / | / | BALf:↓28 Lung:↓28 |
/ | / | BALf:↓28 Lung:↓28 | / | BALf:↓28 Lung:↓28 | / | / | / | / |
| OVA | / | BALf:↓36 Lung:↓36 |
Lung:↓36 | NLF:↓50*. Nasal mucosa:↓49* | / | NLF:↓50*. Nasal mucosa:↓50* |
/ | BALf:↑36 Lung:↑36 | Nasal mucosa:↓50* | / | / | / | / | / | NLF:↓50*. Nasal mucosa:↓50* | / | Lung:↓36 | / | Lung:↑36 | |
| GLY syst. | CS | / | / | / | / | / | / | / | / | / | BALf:↓25 | / | BALf:↓25 | / | / | / | / | / | / | |
| GLY inh. | CS | BALf:↓29 Lung:↓29 | / | / | / | / | / | / | / | / | BALf:↓29 Lung:↓29 |
/ | / | / | / | BALf:↓29 Lung:↓29 | / | Lung:↓29 | BALf:↓29 Lung:↓29 | Lung:↑29 |
| IB inh. | OVA | / | / | / | NLF:↓50*. Nasal mucosa:↓50* | / | NLF:↓50*. Nasal mucosa:↓50* |
/ | / | Nasal mucosa:↓50* | / | / | / | / | / | NLF:↓50*. Nasal mucosa:↓50* | / | / | / | / |
| CdCl2 | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | BALf:≈51 chronic challenge52 | BALf:↓51 ≈ chronic challenge52 | / | / | |
| ACL inh. | Af extract | / | BALf:≈48 | / | BALf:≈48 | / | BALf:≈48 | / | / | / | / | / | / | / | / | BALf: ≈ TNF (α and β)48 | / | / | / | / |
| 4-DAMP syst. | CS | / | / | / | / | / | / | / | / | / | / | / | / | BALf:↓53 | / | / | / | / | / | / |
| LPS | / | / | / | Lung:↓26 | / | / | / | / | Lung:↓26 | / | / | / | / | / | Lung:↓26 | / | / | / | / | |
| Mepenzolate bromide inh. | PPE | / | / | / | / | / | / | / | / | / | BALf:↓54 | / | BALf:≈54 | BALf:↓54 | / | BALf:↓54 | / | / | / | / |
| CS | / | / | / | / | / | / | / | / | / | BALf:↓54*. Lung:≈54* |
/ | BALf:↓54*. Lung:↓54* | BALf:↓54*. Lung:↓54* |
/ | BALf:↓54*. Lung:≈54* | / | / | / | / | |
| Anisodamine syst. | OVA | / | BALf:↓55 | / | / | / | / | / | BALf:↑55 | / | / | / | / | / | / | / | / | / | / | / |
Note: *Intranasal or intratracheal instillation.
Abbreviations: ACL, aclidinium; Af, Aspergillus fumigatus; BALf, bronchoalveolar lavage fluid; BCQB, bencycloquidium bromide; CdCl2, cadmium chloride; COPD, chronic obstructive pulmonary disease; CS, cigarette smoke; GLY, glycopyrronium; H1N1, influenza virus A/PR/8/34; IB, ipratropium bromide; IFN, interferon; IL, interleukin; KC, keratinocyte-derived chemokine; LPS, lipopolysaccharide; MAC-1, macrophage-1 antigen; MCP, monocyte chemoattractant protein; MIP, macrophage inflammatory protein; MMP, matrix metalloproteinase; NA, not available; NLF, nasal lavage fluid; OVA, ovalbumin; PDCD5, programmed cell death protein 5; PM, particulate matter; ROA, route of administration; RSV, respiratory syncytial virus; TGF- β1, tumor growth factor-beta 1; TIMP, tissue inhibitor of metalloproteinase; TIO, tiotropium bromide or tiotropium bromide hydrate; TNF-α, tumor necrosis factor-alpha; 4-DAMP, 1,1-dimethyl-4-diphenylacetoxypiperidinium iodide.
Table 3.
Impact of Muscarinic Receptor Antagonists on the Inflammatory Cellular Response Induced by Different Pro-Inflammatory Stimuli in Laboratory Animals. Statistically Significant Results with a P<0.05 are Reported in the Table
| Investigated Treatment | Pro-Inflammatory Stimulus | Investigated Outcomes in the in vivo Studies on Laboratory Animals | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total Inflammatory Cell Count | Eosinophils | Macrophages | Neutrophils | Lymphocytes | Monocytes | Basophils | Total Protein Amount | Lung Inflammatory Score | ||
| TIO inh. | OVA | BALf:↓36,44* in advanced-age mice,39 chronic challenge,40 acute and chronic challenge;22 ↑ acute challenge;40≈35,41,42 |
BALf: ↓ in advanced-age mice,39 acute onset and relapse of allergic asthma,36,38* acute challenge,22 chronic challenge;22,40 ↑ acute challenge;40≈35,41–43*. Lung: ↓ in submucosal cartilaginous airways,41 acute onset and relapse of allergic asthma;36,38* ≈ in submucosal and adventitia of non-cartilaginous airways and adventitia of cartilaginous airways,41 total and nerve-associated eosinophils43* |
BALf: ↑ acute challenge;40 ↓ acute challenge,22 chronic challenge;22,40≈35,36,41–43*, acute onset of allergic asthma38* | BALf: ↓ in advanced-age mice;39≈35,41–43*, acute challenge,40 chronic challenge,40 acute onset of allergic asthma38* | BALf: ↓ chronic challenge,22,40 acute onset and relapse of allergic asthma38*;≈35,36,39,41,43*, acute challenge22,40 | / | / | / | Lung: ↓ acute onset and relapse of allergic asthma35,38 |
| OVA + exposure to PM | BALf:↓37 | BALf:↓37 | BALf:↓37 | BALf:↓37 | BALf:↓37 | / | / | / | / | |
| CS | BALf:↓28–31 Lung:↓28,31 Serum:≈31 |
BALf:↓31 Serum:≈31 |
BALf:↓28,31≈29 | BALf:↓28–30≈31 Serum:≈31 |
BALf:↓28,29≈31 Serum:≈31 |
BALf:≈30 Serum:≈31 |
Serum:≈31 | Serum:≈31 | Lung:↓28,31 | |
| CS + H1N1 infection | BALf:↓27 | / | BALf:↓27 | BALf:↓27 | / | / | / | / | / | |
| CS + RSV infection | / | / | BALf:≈27 | BALf:↓27 | / | / | / | / | / | |
| OD | BALf:≈34* | BALf:≈34* | BALf:≈34* | BALf:≈34* | BALf:≈34* | / | / | / | / | |
| House dust mite extract | BALf:≈33* | BALf:≈33* | / | / | / | / | / | / | Lung:↓33* | |
| RB | BALf: ↓ 40%IRB, 60%ERB, and 40%/60%CRB;45 ≈ 50%IRB45 | / | BALf: ↓ 40%IRB and 40%/60%CRB;45 ≈ 50%IRB and 60%ERB45 | BALf: ↓ 40%IRB 50%IRB, 60%ERB, and 40%/60%CRB45 | / | / | / | BALf: ↓ 40%IRB and 40%/60%CRB;45 ≈ 50%IRB and 60%ERB45 | / | |
| CdCl2 | BALf:↓47 | / | BALf:≈47 Lung: ↓ in alveoli, peri-bronchial regions, and parenchyma.47 |
BALf:↓47 Lung: ↓ in alveoli, peri-bronchial regions, and parenchyma47 |
/ | / | / | BALf:↓47 | Lung:↓47 | |
| LPS | BALf:≈30 | / | / | BALf:↓30 Lung: ↓ in cartilaginous, non-cartilaginous airways and parenchyma32 |
/ | BALf:≈30 | / | / | / | |
| Acidic solution | BALf:↓46 Lung:↓46 |
/ | BALf:↓46 | BALf:↓46 | BALf:↓46 | / | / | / | / | |
| BCQB inh. | CS | BALf:↓28 Lung:↓28 |
/ | BALf:↓28 | BALf:↓28 Lung:↓28 |
BALf:≈28 | / | / | / | Lung:↓28 |
| OVA | BALf:↓36 | BALf:↓36 Lung:↓36 Nasal mucosa:↓50* |
BALf:↓36 | / | BALf:≈36 | / | / | / | / | |
| GLY syst. | CS | BALf:↓25 | / | BALf:↓25 | BALf:↓25 | BALf:↓25 | / | / | BALf:↓25 | Lung:↓25 |
| GLY inh. | CS | BALf:↓29 | / | BALf:↓29 Lung: ↓ in alveolar spaces29 |
BALf:↓29 Lung: ↓ in alveolar spaces29 |
BALf:≈29 | / | / | / | / |
| V0162 inh. | OVA | BALf:↓44* | / | / | / | / | / | / | / | / |
| IB inh. | OVA | / | Nasal mucosa:↓50* | / | / | / | / | / | / | / |
| CdCl2 | BALf: ↓ acute challenge;52≈51 chronic challenge52 | / | BALf:≈51 acute and chronic challenge52 | BALf:↓51 acute challenge;52 ≈ chronic challenge52 | / | / | / | BALf: ≈ chronic challenge52 | Lung:↓51 | |
| ACL inh. | CS | / | Lung: ≈ in alveolar septa and airways49 | Lung: ≈ in alveolar septa and airways49 | Lung: ↓ in alveolar septa49 | / | / | / | / | / |
| Af extract | / | BALf:↓48 | BALf:≈48 | BALf:≈48 | BALf:≈48 | / | / | BALf:↓48 | / | |
| 4-DAMP syst. | CS | BALf:↓53 | / | BALf:↓53 | BALf:↓53 | BALf:↓53 | / | / | / | / |
| LPS | BALf:↓26 | / | / | BALf:↓26 | / | / | / | / | / | |
| 4-DAMP inh. | PPE | BALf:≈54* | / | / | BALf:≈54* | / | / | / | / | / |
| Mepenzolate bromide inh. | PPE | BALf:↓54 | / | / | BALf:↓54 | / | / | / | / | / |
| CS | Lung:↓54* | / | Lung: ↓ in alveoli54* | Lung:↓54* | / | / | / | / | / | |
| Anisodamine syst. | OVA | BALf:↓55 Lung: ↓ in peribronchial and perivascular regions54 |
BALf:↓55 Lung: ↓ in airway walls55 |
/ | / | / | / | / | / | / |
Note: *Intranasal or intratracheal instillation.
Abbreviations: ACL, aclidinium; Af, Aspergillus fumigatus; BALf, bronchoalveolar lavage fluid; BCQB, bencycloquidium bromide; CdCl2, cadmium chloride; COPD, chronic obstructive pulmonary disease; CRB, combined resistive breathing; CS, cigarette smoke; ERB, expiratory resistive breathing; GLY, glycopyrronium; H1N1, influenza virus A/PR/8/34; IB, ipratropium bromide; IFN, interferon; IL, interleukin; IRB, inspiratory resistive breathing; KC, keratinocyte-derived chemokine; LPS, lipopolysaccharide; MAC-1, macrophage-1 antigen; MCP, monocyte chemoattractant protein; MIP, macrophage inflammatory protein; MMP, matrix metalloproteinase; NA, not available; NLF, nasal lavage fluid; OVA, ovalbumin; PDCD5, programmed cell death protein 5; PM, particulate matter; RB, resistive breathing; ROA, route of administration; RSV, respiratory syncytial virus; TGF- β1, tumor growth factor-beta 1; TIMP, tissue inhibitor of metalloproteinase; TIO, tiotropium bromide or tiotropium bromide hydrate; TNF-α, tumor necrosis factor-alpha; 4-DAMP, 1,1-dimethyl-4-diphenylacetoxypiperidinium iodide.
Tiotropium Bromide
In BALB/cAnNCrl mice exposed to CS and infected with H1N1 influenza virus, nebulized TIO 0.1–0.3 mg/mL reduced the over-expression of IL-1β, IL-6, IFN-γ, and TNF-α in lung tissue, and the number of total inflammatory cells, neutrophils, and macrophages in bronchoalveolar lavage fluid (BALf), with no effect on keratinocyte-derived chemokine (KC/CXCL1).27 In BALB/c mice exposed to CS and infected with respiratory syncytial virus, TIO reduced the number of neutrophils and decreased the levels of IL-6, IFN-γ, TNF-α, and KC in lung tissue, but did not modulate the level of macrophages in BALf.27 In ICR mice exposed to CS, TIO 60 μg/mL via aerosol reduced the level of total inflammatory cells, neutrophils, macrophages, and lymphocytes, and the gene and protein over-expression of IL-1β, KC, monocyte chemoattractant protein (MCP-1), TGF-β1, and TNF-α in BALf and lung tissue.28,29 TIO also modulated the upregulation of MMP-9 and TIMP-1.29 In C57Bl/6J mice exposed to CS, TIO 0.1 mg/mL - 0.3 mg/mL via inhalation reduced the number of total inflammatory cells and neutrophils in lung tissue and BALf, with no modulatory effect on monocytic cell count. TIO also inhibited the release of KC, and the over-expression of IL-6, MCP-1, MIP-2, MIP-1α, TNFα, and LTB4 (−94.00%) in BALf.30 In CS-exposed domestic cats, inhalation of TIO 18 μg reduced the increased concentrations of serum total protein, with no modulatory effect on the total leukocyte and differential cell counts in the blood. At the BALf level, TIO reduced the over-expression of IL-6, IL-8, MCP-1, and TNF-α, and the number of total inflammatory cells, macrophages, and eosinophils, but not neutrophils and lymphocytes. TIO suppressed perivascular and peribronchiolar infiltration of inflammatory cells in lung tissues and improved the lung inflammation scores.31
In C57Bl/6 mice challenged with LPS, aerosolized TIO 0.1 mg/mL – 0.3 mg/mL reduced the total number of inflammatory cells and inhibited the release of IL-6 in BALf. No effect on neutrophils and monocytes counts, and on TNFα, MIP-2, MCP-1, and MIP-1α were detected.30 In Hartley guinea pigs challenged with LPS, nebulized TIO 0.1 mM inhibited neutrophilia in the airways and parenchyma.32
In C57BL/6J mice challenged with house dust mite extract, intranasal treatment with TIO 1 mg/kg – 100 mg/kg did not modulate the total inflammatory cells and eosinophils in BALf, while in lung tissues, TIO dose-dependently reduced the airway inflammation along with the inflammation score.33 In BALB/c mice exposed to organic dust, intranasal TIO 2–200 ng decreased the over-expression of IL-4 and IL-6, with no effect on total and differential inflammatory cell counts, and levels of IL-13, TNF, MCP-1, and MIP-1 in BALf. TIO did not modulate the over-expression of IL-4, IL-6, IL-13, IL-17A, TNF-α, MIP-1, and KC in lung tissue.34
In BALB/c mice challenged with OVA, nebulized TIO 36 μg in 3 mL of sterile physiological saline induced a numerical decreasing trend in the total number of inflammatory cells in BALf, with no modulatory effect on macrophages, eosinophils, neutrophils, and lymphocytes. TIO reduced the pathological score of inflammatory cells infiltration in the airways and expression of programmed cell death 5 in lung tissue and BALf.35 TIO nebulized at 50 μg/mL in saline decreased the total inflammatory cell count, macrophages, and eosinophils, but not lymphocytes in BALf, and prevented the inflammatory reaction induced by the acute exposure to OVA in BALB/c mice. TIO also reduced the OVA-induced release of TGF-β1, IL-4, IL-5, and IL-13 in BALf.22 Nebulized TIO 60 μg/mL administered to ICR mice challenged with OVA prevented the increased number of total leukocytes count in BALf and the infiltration of eosinophils in lung tissue and BALf, with no effect on the accumulation of macrophages and lymphocytes in BALf. TIO also decreased the gene over-expression of IL-5 and MMP-9 in lung tissue without affecting the activity of TIMP-1. In both BALf and lung tissue, TIO reduced the gene and protein over-expression of IL-4 and increased IFN-γ level which was not modulated by OVA.36 In BALB/c mice exposed to ambient particulate matter and challenged with OVA, nebulized TIO 50 μg/mL reduced the increased total inflammatory cell, neutrophil, eosinophil, lymphocyte, and macrophage counts in BALf. TIO also inhibited the over-expression of IL-5, IL-6, IL-13, KC, but it did not modulate the release of IFN-γ in BALf.37
In BALB/c mice challenged with OVA, intranasal instillation of TIO 0.5 mg/mL reduced the airway eosinophilia and lymphocyte count, without modulating the macrophage and neutrophil counts in BALf. TIO reduced the inflammation score, eosinophilia and the number of infiltrating lymphocytes in lung parenchyma.38 In advanced-age BALB/c mice challenged with OVA, intranasal administration of TIO 0.1 mM in 50 μL of phosphate-buffered saline (PBS) reduced the total inflammatory cell count, eosinophils, and neutrophils in BALf. TIO suppressed the pulmonary inflammation in lung tissue and the over-expression of IL-4, IL-5, and IL-13 in BALf, with no effect on the lymphocyte count.39
In a chronic model of asthma in BALB/c mice challenged with OVA for 3 months, intranasal administration of TIO 100 μM in 50 μL of PBS reduced the increased number of total inflammatory cells, macrophages, lymphocytes, eosinophils, but not the levels of neutrophils and IL-5. TIO also induced a trend toward a decrease in the levels of IL-4 and IL-13. Paradoxically, in an acute model of asthma in BALB/c mice challenged with OVA for 4 days, intranasal administration of TIO further increased the number of total inflammatory cells, eosinophils, and macrophages, but not lymphocytes and neutrophils, and the over-expression of IL-4, IL-5, and IL-13 in BALf.40
In Hartley guinea pigs challenged with OVA, nebulized TIO 10–30 μM reduced airway eosinophilia, with no effect on the levels of inflammatory cells number in BALf.41 In further studies, TIO did not prevent the increased levels of inflammatory cells in BALf following OVA challenge.42,43 However, the intratracheal administration of TIO 3 μg reduced the extensive infiltration of leukocytes in BALf induced by OVA challenge.44
In an in vivo model of acute resistive breathing (RB) in healthy rats, inhaled TIO 1 mg/mL prevented the over-expression of IL-1β and IL-6 in lung tissue and reduced the total inflammatory cell, macrophage, and neutrophil counts and the total protein in BALf.45
In BALB/c mice exposed to intra-oesophageal hydrochloric acid (HCl) instillation, inhalation of TIO 5–25 μg/mL reduced the inflammatory cells infiltration in lung tissue and the total inflammatory cell count, macrophages, lymphocytes, and neutrophils in BALf. TIO also reduced IL-8 over-expression in BALf.46 In Sprague-Dawley rats exposed to cadmium chloride (CdCl2), nebulized TIO 70–350 μg/15 mL reduced the number of total inflammatory cells, neutrophils, and protein concentration in BALf, with no effect on the macrophage count. TIO decreased the over-expression of IL-1β, reduced the increased MMP-2 activity in BALf, with no effect on TNF-α and MMP-9. TIO also suppressed the CdCl2-induced infiltration of neutrophils and macrophages in the alveoli, peri-bronchial regions and parenchyma, thus reducing the inflammatory scores associated with the severity and extent of histological injuries.47
Aclidinium
In BALB/c mice challenged with Aspergillus fumigatus extract, aerosolized ACL 1 mg/mL reduced the total protein count and airway eosinophilia in BALf. ACL did not modulate the number of macrophages, neutrophils, and lymphocytes, as well as the over-expression of IL-4, IL-6, IL-13, and TNF in BALf.48
In Hartley guinea pigs exposed to CS, treatment with nebulized ACL 30 μg/mL attenuated the CS-induced infiltration of neutrophils in the alveolar septa, with no difference detected in the number of macrophages or eosinophils.49
Glycopyrronium Bromide
In C57BL/6J mice subchronically exposed to CS, intraperitoneal injection of GLY 3 mg/kg reduced the lung inflammatory score, total protein concentration, total inflammatory cell count, macrophages, lymphocytes, neutrophils, and the over-expression of MCP-1 and MIP-2 in BALf.25
In ICR mice exposed to CS, pretreatment with aerosolized GLY 150–600 μg/mL reduced the number of total inflammatory cells, neutrophils, macrophages, but not lymphocytes, and decreased the gene and protein over-expression of IL-1β, TNF-α, MCP-1, and TGF-β1 in BALf and lung tissue. GLY also reduced the infiltration of neutrophils and macrophages in the alveolar spaces and improved the CS-upregulated activity of MMP-9 and TIMP-1 in lung tissue.29
Ipratropium Bromide
In Sprague-Dawley rats challenged with OVA, intranasal instillation of IB 3 mg/kg suppressed the infiltration of eosinophils in the nasal mucosa, reduced the gene and protein over-expression of IL-6, IL-13, and TNF-α in NLF and nasal mucosa, and inhibited the nuclear translocation of NF- κB p65 and p50 subunits in nasal mucosa.50
In Sprague-Dawley rats exposed to CdCl2, pretreatment with nebulized IB 0.04–0.20 mg/20 mL reduced the number of neutrophils and the activity of MMP-9 in BALf, with no modulatory action on macrophages, total inflammatory cell count, and MMP-2. IB suppressed the extent of lung injuries and reduced the severity of inflammatory cell infiltration in lung tissue, leading to improvement in lung inflammation score.51 In Sprague-Dawley rats chronically exposed to CdCl2, pretreatment with nebulized IB 0.20 mg/20 mL did not exert a modulatory effect on the increased protein concentration, MMP-2 and MMP-9 activity, and on the number of total inflammatory cells, neutrophils, macrophages in BALf. Conversely, single and repeat inhalation of IB followed by an acute exposure to CdCl2 reduced the total inflammatory cell count and the neutrophil count, with no modulatory effect on macrophages.52
Bencycloquidium Bromide
In ICR mice exposed to CS, aerosol pre-treatment with bencycloquidium bromide (BCQB) 75–300 μg/mL reduced the accumulation of total inflammatory cells and neutrophils in BALf, and the score of inflammatory cell infiltration in lung tissues. BCQB also inhibited the gene and protein over-expression of KC/CXCL1 and MCP-1 in BALf and lung tissues, and TNF-α gene over-expression in lung tissues. BCQB reduced the macrophage count and TNF-α release in BALf, and the gene and protein over-expression of IL-1β in BALf and lung tissues, but no change in lymphocyte accumulation was observed in BALf.28
In Sprague-Dawley rats challenged with OVA, intranasal instillation of BCQB 0.75–3 mg/kg inhibited the aggregation of mast cells and the nuclear translocation of NF-κB p65 and p50 subunits in nasal mucosa. BCQB reduced the over-expression of IL-6, IL-13, and TNF-α in nasal lavage fluid (NLF) and nasal mucosa, along with the infiltration of eosinophils in nasal mucosa. BCQB also reduced the over-expression of IL-13 in NLF but had no modulatory effect on IL-6, TNF-α, and the eosinophils present in the nasal mucosa.50
In ICR mice challenged with OVA, nebulized BCQB 60–240 μg/mL reduced the total number of leukocytes and eosinophils, but not lymphocytes in BALf. BCQB decreased the gene over-expression of IL-5 and MMP-9 and increased the gene expression of TIMP-1 in lung tissue, whereas in both BALf and lung tissue it reduced the gene and protein expression of IL-4 and increased IFN-γ. BCQB attenuated eosinophil infiltration in lung tissue and inhibited the accumulation of macrophages in BALf.36
1,1-Dimethyl-4-Diphenylacetoxypiperidinium Iodide
In C57Bl/6NTac wild-type mice exposed to CS, intraperitoneal administration of 4-DAMP 1 mg/kg reduced the number of total inflammatory cells, macrophages, lymphocytes, neutrophils, and the release of KC in the BALf.53 In Kunming mice challenged with LPS, intraperitoneal administration of 4-DAMP 1 mg/kg reduced the BALf number of total inflammatory cells and the percentage of neutrophils, and in lung tissue, it reduced the level of IL-6 and the degradation of IKB-α promoted by LPS stimulation. 4-DAMP also reduced the concentration of TNF-α in lung tissue.26
Single intratracheal administration of 4-DAMP 3.8–38.0 μg/kg to ICR mice stimulated with porcine pancreatic elastase (PPE), had no modulatory effect on the number of total inflammatory cells and neutrophil count in BALf.54
Mepenzolate
In DBA/2 and ICR mice exposed to CS, intratracheal administration of mepenzolate 38.0 μg/kg reduced the total number of inflammatory cells, neutrophils, and alveolar macrophages in lung tissue, and decreased the gene over-expression of MIP-2 and KC, but not MCP-1 and TNF-α. Mepenzolate reduced the protein over-expression of MIP-2, KC, MCP-1, and TNF-α in BALf.54
In ICR mice challenged with PPE, inhaled mepenzolate 0.38–38.0 μg/kg reduced the total number of leukocytes and neutrophils, and the over-expression of TNF-α, MCP-1, and KC, but not MIP-2 in the BALf. Mepenzolate partially restored the gene and protein over-expression of HDAC2, as well as HDAC enzymatic activity, and suppressed the level of phosphorylated NF-κB, without exerting a modulatory effect on IκB-α.54
Anisodamine
In BALB/c mice challenged with OVA, intraperitoneal administration of anisodamine 0.75–3 mg/kg inhibited the influx of total inflammatory cells and eosinophils in BALf. Anisodamine suppressed the peribronchial and perivascular infiltration of inflammatory cells in the lungs, reduced the influx of eosinophils into airway walls and the over-expression of IL-4 (−83.00%), and increased the level of IFN-γ in BALf.55
V0162
In guinea pigs challenged with OVA, intratracheal administration of V0162 50 μg reduced the extensive infiltration of leukocytes in BALf (−27.00%).44
Anti-Inflammatory Effect of Muscarinic Receptor Antagonists in Clinical Studies
An overview concerning the anti-inflammatory impact of TIO administered via inhalation in COPD patients is reported in Table 4.
Table 4.
Impact of TIO 18 μg on Humoral and Cellular Inflammatory Responses Evaluated in COPD Patients. Statistically Significant Results with a P<0.05 are Reported in the Table
| Investigated Treatment | Outcomes Investigated in the Clinical Studies | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IL-6 | IL-8 | CRP | TNF-α | HDAC Activity | LTB4 | MMP-9 | SSA | Fibrinogen | White Blood Cells | Total Inflammatory Cells | Eosinophils | Macrophages | Neutrophils | |
| TIO 18 μg | Serum:≈60,61 EBC:≈57 Sputum:≈61 | Serum:≈60 Sputum:↑59,61 | Serum:≈59–61 | Serum:≈60 EBC:≈57 |
≈58 | Supernatant of fMLP activated blood neutrophils primed with GM-CSF:↓56* | Sputum:↑59 | Serum:≈60 | Plasma:≈60 | Blood:↓60 | Sputum:≈59 | Sputum:≈59 | Sputum:≈59 | Sputum:≈59 |
Note: *Performed ex vivo.
Abbreviations: CRP, C-reactive protein; EBC, exhaled breath condensate; fMLP, formyl-L-methionyl-L-leucyl-phenylalanine; GM-CSF, granulocyte macrophage-colony stimulating factor; HDAC, histone deacetylase; IL, interleukin; LTB4, leukotriene B4; MMP-9, matrix metalloproteinase; SAA, serum amyloid A; TIO, tiotropium bromide; TNF-α, tumor necrosis factor alpha.
Four weeks of treatment with TIO 18 μg reduced the synthesis of LTB4 by blood neutrophils activated with formyl-L-methionyl-L-leucyl-phenylalanine and primed with GM-CSF,56 with no reduction in the release of IL-6 and TNF-α in the exhaled breath condensate of stable COPD patients.57
A 3-month treatment with TIO 18 μg increased the expression of acetylated histone H3 and the release of IL-8 and MMP-9 in induced sputum of COPD patients.58,59 No modulatory effect was detected on HDAC2 expression,58 serum level of C-reactive protein (CRP), and total number of inflammatory cells, macrophages, neutrophils, and eosinophils.59
A 6-month treatment with TIO 18 μg reduced the number of white blood cells but did not modulate the serum levels of CRP, IL-8, serum amyloid A, TNF-α, and fibrinogen.60
Treatment for 1 year with TIO 18 μg increased the concentration of IL-8 in the sputum of smoking COPD patients, without affecting the levels of serum CRP, serum IL-6, and sputum IL-6.61
Quality of Evidence and Risk of Bias
Three out of six clinical studies (50.00%) included in this systematic review were ranked as being of medium quality (Jadad score =3), whereas the other half (50.00%) of them was characterized by low-quality level (Jadad score <3).
The traffic light plot for the assessment of the risk of bias of each included clinical study is reported in Figure 1A, and the weighted plot for the assessment of the overall risk of bias by domains is shown in Figure 1B.
Figure 1.
Assessment of the risk of bias via the Cochrane RoB 2 tool displayed by means of a traffic light plot of the risk of bias of each included clinical study (A), and weighted plot for the distribution of the overall risk of bias within each bias domain via the Cochrane RoB 2 tool (B) (n=6 clinical studies). Traffic light plot reports five risk of bias domains: D1, bias arising from the randomization process; D2, bias due to deviations from intended intervention; D3, bias due to missing outcome data; D4, bias in measurement of the outcome; D5, bias in selection of the reported result; Yellow circle indicates some concerns on the risk of bias and green circle represents low risk of bias.
Note: Figure image was created using https://mcguinlu.shinyapps.io/robvis/.
Abbreviation: RoB, risk of bias.
Most of the clinical studies had a low risk of bias for the randomization process (3 [50.00%]), missing outcome data (5 [83.33%]), and selection of the reported results (6 [100.00%]). Of the six clinical trials, three (50.00%) had a high risk of bias due to deviations from intended intervention whereas four studies (66.67%) had some concerns on the risk of bias in the domain of measurement of the outcomes.
Discussion
The evidence originating from the present systematic review indicates that therapy with muscarinic receptor antagonists in general, and LAMAs, in particular, may exert significant anti-inflammatory effect from bench-to-bedside. Among the approved LAMAs, most of the current evidence on the anti-inflammatory activity in the airways is related to TIO. Evidence demonstrated a reduction in the synthesis and release of cytokines and chemokines, as well as the total and differential number of inflammatory cells, induced by several pro-inflammatory different stimuli such as ACh, HCl, CS, CdCl2, IL-1β, LPS, OVA, PHA, RB, TGF-β, and viral infections. Effectively, it has been thoroughly documented that the mode of action of TIO consists of a bronchodilator effect and reduced mucus secretion. Interestingly, preclinical evidence also suggests an anti-inflammatory effect of TIO.7 Conversely, few data are currently available for ACL and GLY, whereas no studies on the potential anti-inflammatory effect of umeclidinium have been reported.
In pre-clinical settings, the most direct way to deliver pulmonary drugs to the target tissue is via intratracheal, intranasal, or aerosol delivery. Although intranasal instillation and nebulization are very different administration techniques,62 it has been demonstrated that both are effective at achieving dose-dependent lung deposition and display a comparable systemic exposure.63
Interestingly, it has been documented that TIO may increase the percentage of apoptotic CD3+ and CD8+ PBT-cells and reduced the apoptotic CD4+ cells in COPD patients.21 This contradictory finding could be explained by a different degree of binding between Ach and T lymphocytes, therefore it can be hypothesized that muscarinic receptor stimulation regulates the apoptosis and restores the physiological balance between CD4+ and CD8+ PBT-cells.64
Paradoxically, long-term treatment with TIO was associated with an increased concentration of IL-8 and MMP-9 in the sputum of COPD patients. This evidence can be the result of the inhibitory action of TIO exerted on mucus-secreting airway goblet cells, thus leading to a reduced amount of mucus secretion and a higher concentration of the mediators in the sputum.59,61
In any case, the evidence of this qualitative synthesis supports the current hypothesis that non-neurogenic Ach contributes to airway inflammation via activation of mAchRs.65 In fact, multiple pro-inflammatory stimuli can lead to the release of Ach from respiratory epithelial cells, fibroblasts, and inflammatory cells, thus producing various biological reactions in an auto/paracrine manner.66
Blockade of muscarinic M3 receptors by LAMA might result in anti‐inflammatory effects in the airways; such effects might be increased by the concomitant activation of beta2 receptors by LABA.13 However, clinical studies including airway inflammatory biomarkers in patients with COPD are required to assess these pharmacological effects.
In this respect, the blockage of M3 mAchR elicited by LAMAs seems to result in anti-inflammatory effects in the airways, which could be synergistically increased by concomitant treatment with LABAs.65 Recent evidence further supports the beneficial synergistic interaction at the level of human medium bronchi and small airways not only when TIO is combined with the long-acting β2 adrenoceptor agonist (LABA) olodaterol (OLO) as LABA/LAMA fixed-dose combination (FDC),67 but also when a LAMA is combined with an inhaled corticosteroid (ICS),68 and when ICSs, LABAs and LAMAs are combined in triple FDCs.69 Overall, the currently available data on the anti-inflammatory effect of LAMAs support the evidence coming from studies performed ex vivo concerning the release of non-neurogenic Ach in the airways.9
The evidence arising from clinical trials specifically designed to assess the anti-inflammatory profile of LAMAs has been focused exclusively on TIO. Certainly, TIO demonstrated short- and long-term anti-inflammatory activity in COPD, although it did not modulate all the pro-inflammatory investigated outcomes. These clinical studies were performed by administering TIO at 18 μg via the HandiHaler device in non-randomized clinical trials.56–61 This represents the main limitation of this systematic review, as there is an unmet need to understand whether reaching small airways by delivering TIO at 5 μg via Respimat device may further improve the anti-inflammatory activity of this LAMA. This is a hypothesis based on the recent evidence from randomized controlled trials (RCTs) that TIO alone, or in combination with an ICS and/or a LABA, is effective in reducing the risk of COPD and asthma exacerbation.70–72
In this respect, it seems that TIO at 5 μg via Respimat may lead to ceiling effect that, in turn, may effectively modulate pulmonary inflammation.73 The clinical benefit of TIO in reducing the risk of COPD exacerbation is further confirmed by a recent meta-analysis demonstrating that treatment with LAMA in stable COPD produced a lower incidence of exacerbation compared to LABA.74 In asthmatic patients, the exploratory analyses conducted by Szefler et al72 and Casale et al75 confirmed the efficacy of TIO added to ICSs, with or without other controllers, in improving the frequency of exacerbations.
Probably the anti-inflammatory action of LAMAs is directly accountable for the reduction in the risk of exacerbation. However, although current pre-clinical evidence supports this hypothesis, some studies in COPD patients provided contrasting results. According to Powrie et al.61 TIO-induced prevention of COPD exacerbations is rather associated with an improvement in dynamic hyperinflation or airway mucus hypersecretion. As argued by the authors, the main limitation of the study was the use of sputum samples to quantify inflammatory markers, as they are difficult to be obtained and are characterized by high variability in cytokine levels.61 Furthermore, TIO could have reduced mucus secretion, thus producing a higher release of mediators in sputum.61 Measurement of sputum markers may not be fully reflective of the changes occurring in the bronchial mucosa,76 therefore further clinical investigations are needed, especially to identify the appropriate inflammatory markers to measure in bronchial biopsies.77
Evidence from experimental models documented that LAMAs reduces mucus production,78 and in particular, COPD patients reported a subjective improvement in sputum clearance upon treatment with TIO.61 Mucus hypersecretion is indeed an important feature of chronic obstructive respiratory disorders such as COPD and asthma, and contributes to alter the quality of life, morbidity and mortality of patients.79
The M3 mAchR represents the dominant subtype in the regulation of neuronally mediated mucus secretion from submucosal glands and goblet cells,80,81 and TIO is, in particular, one of the LAMAs with higher selectivity for this receptor.65 MUC5AC gene is the main mucin gene expressed in human airway epithelial cells,79 and TIO was reported to reduce the number of MUC5AC-positive goblet cell in a guinea pig model,82 mucus gland hypertrophy,32 and prevented neutrophil elastase-induced goblet cell metaplasia in mice,83 an effect that seemed related to a reduced recruitment of neutrophils in vivo.82,83 Indeed, these mechanisms may also contribute to an indirect anti-inflammatory effect leading to clinical benefits.
In any case, recent investigations provide the evidence that TIO 5 μg via Respimat is effective in improving lung function, asthma control, and exacerbation risk when given as add-on therapy in children, adolescents, and adult patients independent of the markers of T2 inflammation, namely total IgE and blood eosinophil counts.72,75
Therefore, there is the rational for administering TIO Respimat as add-on therapy with no requirement for phenotyping patients before treatment.72,75
Indeed, the scientific interest in TIO in asthma is further proved by the number of RCTs registered in the ClinicalTirals.gov database and reporting results for the efficacy and the safety profile of TIO 5 μg via Respimat in children and adolescents (8 studies) and adults (17 studies) patients (Table 5). Considering that Respimat permits to optimize the delivery of TIO 5 μg into the small airways, it is expected that the anti-inflammatory effect of TIO via Respimat may be superior to that elicited by TIO via HandiHaler because the non-neuronal cholinergic system, and related inflammation, is prevalent at the level of small airways.9 Effectively, across the currently available LAMAs, only TIO mostly 5 μg once-daily via Respimat is recommended as an add-on therapy and controller option in asthmatic patients at Steps 4 and 5.2
Table 5.
Search Details for “Respimat” and “Asthma” in the ClinicalTrials.gov Database by Applying the Filters “with Results” and “Interventional” (Last Update July 28th 2020)
| Terms Synonyms |
Search Results* | Entire Database** |
|---|---|---|
| Respimat | 25 studies | 191 studies |
|
Asthma Asthmatic |
25 studies – |
3778 studies 550 studies |
Notes: – no studies found, *number of studies in the search results containing the term or synonym; **number of studies in the entire database containing the term or synonym.
Conclusions
A large pre-clinical body of evidence supports the beneficial impact of TIO against airway inflammation. Further well-designed RCTs are needed to better elucidate the anti-inflammatory mechanisms leading to the protective effect of LAMAs against the risk of exacerbation via identifying suitable biomarkers. Finally, but not less important, head-to-head comparisons across the approved LAMAs performed in human ex vivo experimental settings via translational research could better characterize the specific anti-inflammatory profile of each antimuscarinic agent.
Funding Statement
Boehringer Ingelheim Italia (Medical Affairs, Milan, Italy) unconditionally supported L.C. exclusively for performing the literature search on the impact of muscarinic receptor antagonists on airway inflammation, regardless of writing a paper and regardless of any potential publication.
Abbreviations
Ach, acetylcholine; ACL, aclidinium; AHR, airway hyperresponsiveness; ASM, airway smooth muscle; BALf, bronchoalveolar lavage fluid; BCQB, bencycloquidium bromide; Cch, carbachol; CdCl2, cadmium chloride; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; CS, cigarette smoke; CSE, cigarette smoke extract; GLY, glycopyrronium; GM-CSF, granulocyte-macrophage colony-stimulating factor; HCl, hydrochloric acid; HDAC2, histone deacetylase 2; IB, ipratropium bromide; IFN-γ, interferon-gamma; IκB, inhibitor of NF-κB; Iκκα, inhibitor kappa kinase alpha; IL, interleukin; KC/CXCL1, keratinocyte-derived chemokine; LAMA, long-acting muscarinic receptor antagonist; LPS, lipopolysaccharide; LTB4, leukotriene B4; mAchR, muscarinic acetylcholine receptor; MAC-1, macrophage-1 antigen; MCP-1, monocyte chemoattractant; MIP, macrophage inflammatory protein; MMP, metalloproteinase; NF-κB, nuclear factor-κB; NLF, nasal lavage fluid; OVA, ovalbumin; PBT, peripheral blood T; PHA, phytohemagglutinin; PPE, porcine pancreatic elastase; RB, resistive breathing; TGF-β1, tumor growth factor-beta 1; TIMP, tissue inhibitor of metalloproteinase; TIO, tiotropium bromide; TNF-α, tumor necrosis factor-alpha; 4-DAMP, 1,1-dimethyl-4-diphenylacetoxypiperidinium iodide.
Author Contributions
All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agreed to be accountable for all aspects of the work.
Disclosure
L.C. has participated as an advisor in scientific meetings under the sponsorship of Boehringer Ingelheim and Novartis; received nonfinancial support from AstraZeneca; a research grant partially funded by Chiesi Farmaceutici, Boehringer Ingelheim, Novartis, and Almirall; is or has been a consultant to ABC Farmaceutici, Edmond Pharma, Zambon, Verona Pharma, and Ockham Biotech; and his department was funded by Almirall, Boehringer Ingelheim, Chiesi Farmaceutici, Novartis, and Zambon.
A.Co. participated as a lecturer and speaker in scientific meetings and courses under the sponsorship of AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Menarini Group and Zambon.
B.L.R. has no conflict of interest to declare.
M.M. has no conflict of interest to declare.
A.Ch. received grants from Menarini and Astra Zeneca, and personal fee from Chiesi.
P.R. participated as a lecturer and advisor in scientific meetings and courses under the sponsorship of Almirall, AstraZeneca, Biofutura, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Menarini Group, Mundipharma, and Novartis, and her department was funded by Almirall, Boehringer Ingelheim, Chiesi Farmaceutici Novartis, and Zambon.
The authors report no other potential conflicts of interest for this work.
References
- 1.Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of COPD – 2020 Report. 2020. Available from: https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf. Accessed July28, 2020.
- 2.Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2020 Available from: https://ginasthma.org/wp-content/uploads/2020/06/GINA-2020-report_20_06_04-1-wms.pdf. Accessed July28, 2020.
- 3.Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2020;55:1. doi: 10.1183/13993003.00588-2019 [DOI] [PubMed] [Google Scholar]
- 4.Canning BJ. Reflex regulation of airway smooth muscle tone. J Appl Physiol. 2006;101(3):971–985. doi: 10.1152/japplphysiol.00313.2006 [DOI] [PubMed] [Google Scholar]
- 5.Gelb AF, Nadel JA. Affirmation of the adoration of the vagi and role of tiotropium in asthmatic patients. J Allergy Clin Immunol. 2016;138(4):1011–1013. doi: 10.1016/j.jaci.2016.06.024 [DOI] [PubMed] [Google Scholar]
- 6.Gosens R, Zaagsma J, Meurs H, Halayko AJ. Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respir Res. 2006;7:73. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Mansfield L, Bernstein JA. Tiotropium in asthma: from bench to bedside. Respir Med. 2019;154:47–55. doi: 10.1016/j.rmed.2019.06.008 [DOI] [PubMed] [Google Scholar]
- 8.Alagha K, Palot A, Sofalvi T, et al. Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases. Ther Adv Chronic Dis. 2014;5(2):85–98. doi: 10.1177/2040622313518227 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Cazzola M, Calzetta L, Puxeddu E, et al. Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells. Respir Res. 2016;17(1):70. doi: 10.1186/s12931-016-0386-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. doi: 10.1186/2046-4053-4-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12. doi: 10.1016/0197-2456(95)00134-4 [DOI] [PubMed] [Google Scholar]
- 12.Higgins JPT, Savović J, Page MJ, Elbers RG, Sterne JAC. Chapter 8: assessing risk of bias in a randomized trial. Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. 2019;205–228. Available from http://www.training.cochrane.org/handbook.
- 13.Albano GD, Bonanno A, Moscato M, et al. Crosstalk between mAChRM3 and β2AR, via acetylcholine PI3/PKC/PBEP1/Raf-1 MEK1/2/ERK1/2 pathway activation, in human bronchial epithelial cells after long-term cigarette smoke exposure. Life Sci. 2018;192:99–109. doi: 10.1016/j.lfs.2017.11.034 [DOI] [PubMed] [Google Scholar]
- 14.Anzalone G, Gagliardo R, Bucchieri F, et al. IL-17A induces chromatin remodeling promoting IL-8 release in bronchial epithelial cells: effect of Tiotropium. Life Sci. 2016;152:107–116. doi: 10.1016/j.lfs.2016.03.031 [DOI] [PubMed] [Google Scholar]
- 15.Profita M, Bonanno A, Montalbano AM, et al. β2 long-acting and anticholinergic drugs control TGF-β1-mediated neutrophilic inflammation in COPD. Biochimica Et Biophysica Acta (BBA) Mol Basis Dis. 2012;1822(7):1079–1089. doi: 10.1016/j.bbadis.2012.03.002 [DOI] [PubMed] [Google Scholar]
- 16.Yamaya M, Nishimura H, Hatachi Y, et al. Inhibitory effects of tiotropium on rhinovirus infection in human airway epithelial cells. Eur Respir J. 2012;40(1):122–132. doi: 10.1183/09031936.00065111 [DOI] [PubMed] [Google Scholar]
- 17.Suzaki I, Asano K, Shikama Y, Hamasaki T, Kanei A, Suzaki H. Suppression of IL-8 production from airway cells by tiotropium bromide in vitro. Int J Chron Obstruct Pulmon Dis. 2011;6:439–448. doi: 10.2147/COPD.S23695 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Costa L, Roth M, Miglino N, et al. Tiotropium sustains the anti-inflammatory action of olodaterol via the cyclic AMP pathway. Pulm Pharmacol Ther. 2014;27(1):29–37. doi: 10.1016/j.pupt.2013.11.001 [DOI] [PubMed] [Google Scholar]
- 19.Asano K, Shikama Y, Shoji N, Hirano K, Suzaki H, Nakajima H. Tiotropium bromide inhibits TGF-beta-induced MMP production from lung fibroblasts by interfering with Smad and MAPK pathways in vitro. Int J Chron Obstruct Pulmon Dis. 2010;5:277–286. doi: 10.2147/COPD.S11737 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Vacca G, Randerath WJ, Gillissen A. Inhibition of granulocyte migration by tiotropium bromide. Respir Res. 2011;12:24. doi: 10.1186/1465-9921-12-24 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Profita M, Riccobono L, Montalbano AM, et al. In vitro anticholinergic drugs affect CD8+ peripheral blood T-cells apoptosis in COPD. Immunobiology. 2012;217(3):345–353. doi: 10.1016/j.imbio.2011.07.013 [DOI] [PubMed] [Google Scholar]
- 22.Ohta S, Oda N, Yokoe T, et al. Effect of tiotropium bromide on airway inflammation and remodelling in a mouse model of asthma. Clin Exp Allergy. 2010;40(8):1266–1275. doi: 10.1111/j.1365-2222.2010.03478.x [DOI] [PubMed] [Google Scholar]
- 23.Ferraro M, Di Vincenzo S, Dino P, et al. Budesonide, Aclidinium and Formoterol in combination limit inflammaging processes in bronchial epithelial cells exposed to cigarette smoke. Exp Gerontol. 2019;118:78–87. doi: 10.1016/j.exger.2019.01.016 [DOI] [PubMed] [Google Scholar]
- 24.Milara J, Cervera A, de Diego A, et al. Non-neuronal cholinergic system contributes to corticosteroid resistance in chronic obstructive pulmonary disease patients. Respir Res. 2016;17(1):145. doi: 10.1186/s12931-016-0467-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Hsiao Y-H, Tseng C-M, Su K-C, et al. Glycopyrronium bromide inhibits lung inflammation and small airway remodeling induced by subchronic cigarette smoke exposure in mice. Respir Physiol Neurobiol. 2018;249:16–22. doi: 10.1016/j.resp.2017.12.005 [DOI] [PubMed] [Google Scholar]
- 26.Xu ZP, Yang K, Xu GN, et al. Role of M3 mAChR in in vivo and in vitro models of LPS-induced inflammatory response. Int Immunopharmacol. 2012;14(3):320–327. doi: 10.1016/j.intimp.2012.07.020 [DOI] [PubMed] [Google Scholar]
- 27.Bucher H, Duechs MJ, Tilp C, Jung B, Erb KJ. Tiotropium attenuates virus-induced pulmonary inflammation in cigarette smoke-exposed mice. J Pharmacol Exp Ther. 2016;357(3):606–618. doi: 10.1124/jpet.116.232009 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Zhang SJ, Jiang JX, Ren QQ, Xie QM, Xiong YK. Effects of the inhalation of the m3 receptor antagonist bencycloquidium bromide in a mouse cigarette smoke-induced airway inflammation model. Drug Dev Res. 2015;76(3):123–131. doi: 10.1002/ddr.21248 [DOI] [PubMed] [Google Scholar]
- 29.Shen LL, Liu YN, Shen HJ, et al. Inhalation of glycopyrronium inhibits cigarette smoke-induced acute lung inflammation in a murine model of COPD. Int Immunopharmacol. 2014;18(2):358–364. doi: 10.1016/j.intimp.2013.12.021 [DOI] [PubMed] [Google Scholar]
- 30.Wollin L, Pieper MP. Tiotropium bromide exerts anti-inflammatory activity in a cigarette smoke mouse model of COPD. Pulm Pharmacol Ther. 2010;23(4):345–354. doi: 10.1016/j.pupt.2010.03.008 [DOI] [PubMed] [Google Scholar]
- 31.Kolahian S, Shahbazfar AA, Tayefi-Nasrabadi H, et al. Tiotropium effects on airway inflammatory events in the cat as an animal model for acute cigarette smoke-induced lung inflammation. Exp Lung Res. 2014;40(6):272–287. doi: 10.3109/01902148.2014.905657 [DOI] [PubMed] [Google Scholar]
- 32.Pera T, Zuidhof A, Valadas J, et al. Tiotropium inhibits pulmonary inflammation and remodelling in a guinea pig model of COPD. Eur Respir J. 2011;38(4):789–796. doi: 10.1183/09031936.00146610 [DOI] [PubMed] [Google Scholar]
- 33.John-Schuster G, de Kleijn S, van Wijck Y, et al. The effect of tiotropium in combination with olodaterol on house dust mite-induced allergic airway disease. Pulm Pharmacol Ther. 2017;45:210–217. doi: 10.1016/j.pupt.2017.06.010 [DOI] [PubMed] [Google Scholar]
- 34.Gregory JA, Kemi C, Ji J, et al. Effects of tiotropium bromide on airway hyperresponsiveness and inflammation in mice exposed to organic dust. Pulm Pharmacol Ther. 2018;48:203–210. doi: 10.1016/j.pupt.2017.12.004 [DOI] [PubMed] [Google Scholar]
- 35.Wang J, Diao X, Zhu H, He B. Effect of tiotropium bromide on airway inflammation and programmed cell death 5 in a mouse model of ovalbumin-induced allergic asthma. Can Respir j. 2019;2019:6462171. doi: 10.1155/2019/6462171 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Cao R, Dong X-W, Jiang J-X, et al. M3 muscarinic receptor antagonist bencycloquidium bromide attenuates allergic airway inflammation, hyperresponsiveness and remodeling in mice. Eur J Pharmacol. 2011;655(1–3):83–90. doi: 10.1016/j.ejphar.2011.01.024 [DOI] [PubMed] [Google Scholar]
- 37.Kurai J, Watanabe M, Sano H, et al. Reduces airway inflammation and bronchoconstriction induced by ambient particulate matter in a mouse model of asthma. Int J Environ Res Public Health. 2018;15:6. doi: 10.3390/ijerph15061189 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Bosnjak B, Tilp C, Tomsic C, et al. Tiotropium bromide inhibits relapsing allergic asthma in BALB/c mice. Pulm Pharmacol Ther. 2014;27(1):44–51. doi: 10.1016/j.pupt.2013.09.004 [DOI] [PubMed] [Google Scholar]
- 39.Kang JY, Kim IK, Hur J, et al. Expression of muscarinic receptors and the effect of tiotropium bromide in aged mouse model of chronic asthma. Tuberc Respir Dis (Seoul). 2019;82(1):71–80. doi: 10.4046/trd.2018.0049 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Kang JY, Rhee CK, Kim JS, et al. Effect of tiotropium bromide on airway remodeling in a chronic asthma model. Ann Allergy Asthma Immunol. 2012;109(1):29–35. doi: 10.1016/j.anai.2012.05.005 [DOI] [PubMed] [Google Scholar]
- 41.Kistemaker LE, Bos IS, Menzen MH, Maarsingh H, Meurs H, Gosens R. Combination therapy of tiotropium and ciclesonide attenuates airway inflammation and remodeling in a guinea pig model of chronic asthma. Respir Res. 2016;17:13. doi: 10.1186/s12931-016-0327-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Smit M, Zuidhof AB, Bos SIT, et al. Bronchoprotection by olodaterol is synergistically enhanced by tiotropium in a guinea pig model of allergic asthma. J Pharmacol Exp Ther. 2014;348(2):303–310. doi: 10.1124/jpet.113.208439 [DOI] [PubMed] [Google Scholar]
- 43.Buels KS, Jacoby DB, Fryer AD. Non-bronchodilating mechanisms of tiotropium prevent airway hyperreactivity in a guinea-pig model of allergic asthma. Br J Pharmacol. 2012;165(5):1501–1514. doi: 10.1111/j.1476-5381.2011.01632.x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Devillier P, Garrigue E, D’Auzers G, Monjotin N, Similowski T, Clerc T. V0162 a new long-acting bronchodilator for treatment of chronic obstructive lung diseases: preclinical and clinical results. Respir Res. 2015;16:68. doi: 10.1186/s12931-015-0227-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Toumpanakis D, Loverdos K, Tzouda V, et al. Tiotropium bromide exerts anti-inflammatory effects during resistive breathing, an experimental model of severe airway obstruction. Int J Chron Obstruct Pulmon Dis. 2017;12:2207–2220. doi: 10.2147/COPD.S137587 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Cui Y, Devillier P, Kuang X, et al. Tiotropium reduction of lung inflammation in a model of chronic gastro-oesophageal reflux. Eur Respir J. 2010;35(6):1370–1376. doi: 10.1183/09031936.00139909 [DOI] [PubMed] [Google Scholar]
- 47.Zhao S, Yang Q, Yu Z, et al. Protective effects of tiotropium alone or combined with budesonide against cadmium inhalation induced acute neutrophilic pulmonary inflammation in rats. PLoS One. 2018;13(2):e0193610. doi: 10.1371/journal.pone.0193610 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Damera G, Jiang M, Zhao H, et al. Aclidinium bromide abrogates allergen-induced hyperresponsiveness and reduces eosinophilia in murine model of airway inflammation. Eur J Pharmacol. 2010;649(1–3):349–353. doi: 10.1016/j.ejphar.2010.09.043 [DOI] [PubMed] [Google Scholar]
- 49.Dominguez-Fandos D, Ferrer E, Puig-Pey R, et al. Effects of aclidinium bromide in a cigarette smoke-exposed Guinea pig model of chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2014;50(2):337–346. doi: 10.1165/rcmb.2013-0117OC [DOI] [PubMed] [Google Scholar]
- 50.Long R, Zhou Y, Huang J, et al. Bencycloquidium bromide inhibits nasal hypersecretion in a rat model of allergic rhinitis. Inflammation Res. 2015;64(3–4):213–223. doi: 10.1007/s00011-015-0800-6 [DOI] [PubMed] [Google Scholar]
- 51.Zhang W, Fievez L, Cheu E, et al. Anti-inflammatory effects of formoterol and ipratropium bromide against acute cadmium-induced pulmonary inflammation in rats. Eur J Pharmacol. 2010;628(1–3):171–178. doi: 10.1016/j.ejphar.2009.11.015 [DOI] [PubMed] [Google Scholar]
- 52.Zhang W, Fievez L, Zhang F, et al. Effects of formoterol and ipratropium bromide on repeated cadmium inhalation-induced pulmonary inflammation and emphysema in rats. Eur J Pharmacol. 2010;647(1–3):178–187. doi: 10.1016/j.ejphar.2010.08.028 [DOI] [PubMed] [Google Scholar]
- 53.Kistemaker LE, Bos IS, Hylkema MN, et al. Muscarinic receptor subtype-specific effects on cigarette smoke-induced inflammation in mice. Eur Respir J. 2013;42(6):1677–1688. doi: 10.1183/09031936.00112412 [DOI] [PubMed] [Google Scholar]
- 54.Tanaka K, Ishihara T, Sugizaki T, et al. Mepenzolate bromide displays beneficial effects in a mouse model of chronic obstructive pulmonary disease. Nat Commun. 2013;4:2686. doi: 10.1038/ncomms3686 [DOI] [PubMed] [Google Scholar]
- 55.Xu ZP, Wang H, Hou LN, et al. Modulatory effect of anisodamine on airway hyper-reactivity and eosinophilic inflammation in a murine model of allergic asthma. Int Immunopharmacol. 2011;11(2):260–265. doi: 10.1016/j.intimp.2010.12.001 [DOI] [PubMed] [Google Scholar]
- 56.Santus P, Buccellati C, Centanni S, et al. Bronchodilators modulate inflammation in chronic obstructive pulmonary disease subjects. Pharmacol Res. 2012;66(4):343–348. doi: 10.1016/j.phrs.2012.05.007 [DOI] [PubMed] [Google Scholar]
- 57.Ozol D, Karamanli H, Uysal S, Yigitoglu MR, Yildirim Z. Airway inflammation and tiotropium treatment in stable COPD patients. Turkish j Med Sci. 2014;44(5):804–808. doi: 10.3906/sag-1303-138 [DOI] [PubMed] [Google Scholar]
- 58.Holownia A, Mroz RM, Skopinski T, et al. Tiotropium increases cytosolic muscarinic M3 receptors and acetylated H3 histone proteins in induced sputum cells of COPD patients. Eur J Med Res. 2010;15(Suppl 2):64–67. doi: 10.1186/2047-783X-15-S2-64 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Perng D-W, Tao C-W, Su K-C, Tsai -C-C, Liu L-Y, Lee Y-C. Anti-inflammatory effects of salmeterol/fluticasone, tiotropium/fluticasone or tiotropium in COPD. Eur Respir J. 2009;33(4):778–784. doi: 10.1183/09031936.00115308 [DOI] [PubMed] [Google Scholar]
- 60.Lin Y-H, Liao X-N, Fan -L-L, Qu Y-J, Cheng D-Y, Shi Y-H. Long-term treatment with budesonide/formoterol attenuates circulating CRP levels in chronic obstructive pulmonary disease patients of group D. PLoS One. 2017;12:8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Powrie DJ, Wilkinson TM, Donaldson GC, et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J. 2007;30(3):472–478. doi: 10.1183/09031936.00023907 [DOI] [PubMed] [Google Scholar]
- 62.Fernandes CA, Vanbever R. Preclinical models for pulmonary drug delivery. Expert Opin Drug Deliv. 2009;6(11):1231–1245. doi: 10.1517/17425240903241788 [DOI] [PubMed] [Google Scholar]
- 63.Chiang PC, Alsup JW, Lai Y, Hu Y, Heyde BR, Tung D. Evaluation of aerosol delivery of nanosuspension for pre-clinical pulmonary drug delivery. Nanoscale Res Lett. 2009;4(3):254–261. doi: 10.1007/s11671-008-9234-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Baraldo S, Lokar Oliani K, Turato G, Zuin R, Saetta M. The role of lymphocytes in the pathogenesis of asthma and COPD. Curr Med Chem. 2007;14(21):2250–2256. doi: 10.2174/092986707781696573 [DOI] [PubMed] [Google Scholar]
- 65.Yamada M, Ichinose M. The cholinergic pathways in inflammation: a potential pharmacotherapeutic target for COPD. Front Pharmacol. 2018;9:1426. doi: 10.3389/fphar.2018.01426 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Koarai A, Ichinose M. Possible involvement of acetylcholine-mediated inflammation in airway diseases. Allergol Int. 2018;67(4):460–466. doi: 10.1016/j.alit.2018.02.008 [DOI] [PubMed] [Google Scholar]
- 67.Calzetta L, Rogliani P, Page C, Rinaldi B, Cazzola M, Matera MG. Pharmacological characterization of the interaction between tiotropium bromide and olodaterol on human bronchi and small airways. Pulm Pharmacol Ther. 2019;56:39–50. doi: 10.1016/j.pupt.2019.03.004 [DOI] [PubMed] [Google Scholar]
- 68.Cazzola M, Calzetta L, Rogliani P, Puxeddu E, Facciolo F, Matera MG. Interaction between corticosteroids and muscarinic antagonists in human airways. Pulm Pharmacol Ther. 2016;36:1–9. doi: 10.1016/j.pupt.2015.11.004 [DOI] [PubMed] [Google Scholar]
- 69.Rogliani P, Matera MG, Facciolo F, Page C, Cazzola M, Calzetta L. Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: synergy of triple combination therapy on human airway smooth muscle ex vivo. Br J Pharmacol. 2020;177(5):1150–1163. doi: 10.1111/bph.14909 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70.Calverley PMA, Anzueto AR, Carter K, et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. Lancet Respir Med. 2018;6(5):337–344. doi: 10.1016/S2213-2600(18)30102-4 [DOI] [PubMed] [Google Scholar]
- 71.Rogliani P, Calzetta L, Cazzola M. Is ICS–LAMA an alternative option to treat patients with COPD? Lancet Respir Med. 2018;6(5):316–317. doi: 10.1016/S2213-2600(18)30139-5 [DOI] [PubMed] [Google Scholar]
- 72.Szefler SJ, Vogelberg C, Bernstein JA, et al. Tiotropium is efficacious in 6-to 17-year-olds with asthma, independent of T2 phenotype. J Allergy Clin Immunol Pract. 2019;7(7):2286–2295. doi: 10.1016/j.jaip.2019.03.019 [DOI] [PubMed] [Google Scholar]
- 73.Benfante A, Braido F, Scichilone N. The anti-inflammatory properties of tiotropium. Lancet Respir Med. 2018;6(8):e37. doi: 10.1016/S2213-2600(18)30190-5 [DOI] [PubMed] [Google Scholar]
- 74.Koarai A, Sugiura H, Yamada M, et al. Treatment with LABA versus LAMA for stable COPD: a systematic review and meta-analysis. BMC Pulm Med. 2020;20(1):111. doi: 10.1186/s12890-020-1152-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 75.Casale TB, Bateman ED, Vandewalker M, et al. Tiotropium respimat Add-on is efficacious in symptomatic asthma, independent of T2 phenotype. J Allergy Clin Immunol Pract. 2018;6(3):923–935. doi: 10.1016/j.jaip.2017.08.037 [DOI] [PubMed] [Google Scholar]
- 76.Bateman ED, Rennard S, Barnes PJ, et al. Alternative mechanisms for tiotropium. Pulm Pharmacol Ther. 2009;22(6):533–542. doi: 10.1016/j.pupt.2009.06.002 [DOI] [PubMed] [Google Scholar]
- 77.Barnes NC, Qiu YS, Pavord ID, et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med. 2006;173(7):736–743. doi: 10.1164/rccm.200508-1321OC [DOI] [PubMed] [Google Scholar]
- 78.Martin C, Frija-Masson J, Burgel PR. Targeting mucus hypersecretion: new therapeutic opportunities for COPD? Drugs. 2014;74(10):1073–1089. doi: 10.1007/s40265-014-0235-3 [DOI] [PubMed] [Google Scholar]
- 79.Morcillo EJ, Cortijo J. Mucus and MUC in asthma. Curr Opin Pulm Med. 2006;12(1):1–6. doi: 10.1097/01.mcp.0000198064.27586.37 [DOI] [PubMed] [Google Scholar]
- 80.Rogers DF. Pharmacological regulation of the neuronal control of airway mucus secretion. Curr Opin Pharmacol. 2002;2(3):249–255. doi: 10.1016/S1471-4892(02)00146-7 [DOI] [PubMed] [Google Scholar]
- 81.Gosens R, Zaagsma J, Meurs H, Halayko AJ. Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respir Res. 2006;7(1):73. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 82.Bos IS, Gosens R, Zuidhof AB, et al. Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparison. Eur Respir J. 2007;30(4):653–661. doi: 10.1183/09031936.00004907 [DOI] [PubMed] [Google Scholar]
- 83.Arai N, Kondo M, Izumo T, Tamaoki J, Nagai A. Inhibition of neutrophil elastase-induced goblet cell metaplasia by tiotropium in mice. Eur Respir J. 2010;35(5):1164–1171. doi: 10.1183/09031936.00040709 [DOI] [PubMed] [Google Scholar]